RxDoctor Payments Data

Heather Smith, APRN

Nurse Practitioner · Daytona Beach, FLNPI 1225775729

Payments from drug & device makers

$1,718in general payments, 2019–2025

Across 34 payments — averaging $50.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$433
  • Johnson & Johnson$273
  • Teva Pharmaceuticals USA, Inc.$121
  • Acadia Pharmaceuticals Inc$120
  • Novartis$118
  • Sumitomo Pharma America, Inc.$116
  • plus $537 from 14 others

What the payments were for

  • Food & beverage$1,718100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,718 in reported general payments places this provider in the 80th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$91,478
Medicare patients
152
Services billed
1,189

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban83$28,351
TradjentaLinagliptin18$9,232
TrulicityDulaglutide12$8,951
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,293
XareltoRivaroxaban13$7,227
AbrysvoRsv Vacc, Pref A And Pref B/Pf16$5,072
Tresiba Flextouch U-100Insulin Degludec14$4,518
Duloxetine Hcl34$1,879
Methazolamide11$1,741
Atorvastatin Calcium113$1,680
Pregabalin66$1,353
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$1,307
Midodrine Hcl23$1,253
Tamsulosin Hcl57$1,201
Levetiracetam38$1,001

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$18$33,42399 claims
Johnson & JohnsonXarelto$273$7,22713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Daytona Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →